404 related articles for article (PubMed ID: 15235103)
1. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
3. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Dai Y; Rahmani M; Dent P; Grant S
Mol Cell Biol; 2005 Jul; 25(13):5429-44. PubMed ID: 15964800
[TBL] [Abstract][Full Text] [Related]
4. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
[TBL] [Abstract][Full Text] [Related]
5. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Rosato RR; Almenara JA; Yu C; Grant S
Mol Pharmacol; 2004 Mar; 65(3):571-81. PubMed ID: 14978235
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Almenara J; Rosato R; Grant S
Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
[TBL] [Abstract][Full Text] [Related]
8. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
9. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Pei XY; Dai Y; Grant S
Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
[TBL] [Abstract][Full Text] [Related]
10. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Dasmahapatra G; Almenara JA; Grant S
Mol Pharmacol; 2006 Jan; 69(1):288-98. PubMed ID: 16219908
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Rosato RR; Almenara JA; Cartee L; Betts V; Chellappan SP; Grant S
Mol Cancer Ther; 2002 Feb; 1(4):253-66. PubMed ID: 12467221
[TBL] [Abstract][Full Text] [Related]
14. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.
Vrana JA; Decker RH; Johnson CR; Wang Z; Jarvis WD; Richon VM; Ehinger M; Fisher PB; Grant S
Oncogene; 1999 Nov; 18(50):7016-25. PubMed ID: 10597302
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Rahmani M; Yu C; Reese E; Ahmed W; Hirsch K; Dent P; Grant S
Oncogene; 2003 Sep; 22(40):6231-42. PubMed ID: 13679862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]